4D Molecular Therapeutics Inc.

FDMT | NASDAQ

Price Alert Chart Builder DCF Calculator

$15.24

+$0.02 (+0.13%)

At close: Sep 21, 2026, 4:00 PM ET

$15.17

-$0.07 (-0.46%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.13%

(1D)

Rating

Updated: Sep 4, 2026

27.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $796.69M

1D Range

14.68 15.46

52W Range

6.47 16.93

Valuation (TTM)

PE -5.60

PB 1.95

EV/EBITDA -2.43

Valuation (NTM)

Forward PE N/A

Forward PEG 5.03

Price Target $26

Cash Flow

FCF Yield -19.7%

SBC Adj. FCF Yield -22.2%

SBC Impact -13.0%

Margins

Gross Margin 42.0%

Operating Margin -223.4%

FCF Margin -177.6%

Growth (CAGR)

Revenue 3Y | 5Y 238.0% | 30.8%

Dil EPS 3Y | 5Y -6.3% | 3.4%

FCF 3Y | 5Y -25.2% | -15.7%

Returns

ROA -36.4%

ROE -41.3%

ROIC -43.8%

Financial Health

Net Cash

$341.7M

Current Ratio 8.03

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's d...

Sector Healthcare

Industry Biotechnology

Employees 196

IPO Date Dec 10, 2020

Website www.4dmoleculartherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$26

Upside

+70.60%

Buy (5)

Hold (0)

Sell (0)

Analyst Details ➞